Friday, November 28, 2025

dm strengthens its healthcare strategy and will launch a dedicated mail-order pharmacy in 2025

dm is accelerating its transformation in the healthcare segment and has announced that it will launch its own mail-order pharmacy in 2025. This strategic step positions the company as a relevant long-term health partner, extending its portfolio to include OTC medicines and pharmacy-exclusive cosmetics. Operated in Bor, Czech Republic, the initiative represents a core milestone in dm’s healthcare expansion.

dm closed the 2024/2025 financial year with a strong revenue increase to EUR 19.197 billion, expanding its market leadership across Europe. The workforce grew to 93,426 employees, and customer activity continues to rise, with 12.5 million users of the dm app.

A major growth driver is dm’s consistent omnichannel strategy, integrating stationary retail, online shopping, express delivery, and in-store pickup. Online sales show double-digit growth, supported by the upcoming second distribution center in Heideloh near Leipzig, set to open in February 2026.

The company also invests heavily in modernizing its extensive network of 4,189 stores. More than EUR 250 million will be allocated to modernization and digital enhancements. dm continues the rollout of self-service checkouts and expands its network of pickup stations, including new 24/7 pickup solutions currently in testing.

Behind the scenes, dm advances its digital transformation through SAP S/4 HANA and innovative AI tools such as dmGPT, designed to improve product development, communication processes, and customer interaction.

A key focus area is the expansion of healthcare services. The mail-order pharmacy is only the beginning: dm is testing eye screening with Skleo Health, AI-powered skin analysis with dermanostic, and selected blood diagnostics via Aware Health. Under the Mivolis brand, dm has launched its first laboratory-based self-tests, expanding its accessible preventive offerings.

According to a Sempora study, nearly 70 percent of citizens would purchase OTC medicines from dm, highlighting strong consumer trust. In addition, dm maintains leadership in the organic dry goods segment, generating over EUR 1 billion in bio-category revenue.

In sustainability, dm pursues ambitious energy initiatives. Sixty new photovoltaic systems will be installed across Europe, while from 2026, a Power Purchase Agreement will supply around 20 percent of electricity needs through wind and solar energy. In collaboration with LanzaTech, dm will launch CO₂-based surfactants in Denkmit detergents in November 2025. The company remains on track to reach net-zero emissions by 2045.

High satisfaction scores and top employer rankings affirm dm’s strategic course. With targeted investments in quality, digital innovation, preventive health, and sustainability, dm further strengthens its position in the European healthcare and retail landscape.